Browse the evidence

Healthcare professionals should assess biochemical hyperandrogenism using validated tandem mass spectrometry (LC-MS/MS) for testosterone, avoiding direct immunoassays due to their limited accuracy.

When getting blood work for PCOS, ensure your doctor orders testosterone testing via 'tandem mass spectrometry' (LC-MS/MS). This is the gold standard for accuracy. Avoid standard immunoassays if possible.

Exenatide treatment significantly reduces dopamine transporter (DAT) availability in the striatum, caudate, and putamen in patients with Alcohol Use Disorder.

Exenatide changes the brain's dopamine transporter levels in key reward areas, which may help compensate for the dopamine deficits seen in chronic alcohol use. This is a biological mechanism, not a direct measure of drinking behavior.

Prophylactic administration of uPAR-targeting CAR T cells in young mice prevents the development of age-related metabolic dysfunction and maintains exercise capacity into old age.

Treating young organisms with senolytic CAR T cells can prevent metabolic decline and maintain physical fitness into old age. This suggests that early intervention might be more effective than late-stage treatment.

Combining Endoscopic Gastric Remodeling (EGR) with a GLP-1 Receptor Agonist (GLP-1RA) initiated within 6 months of the procedure yields significantly greater weight loss (23.7% TWL) than EGR monotherapy or sequential therapy.

If you are considering Endoscopic Gastric Remodeling (EGR), ask about starting a GLP-1RA (like semaglutide or liraglutide) within 6 months of the procedure. This specific combination yields significantly better weight loss (approx. 24%) than either treatment alone. Avoid taking other types of weight loss medications for more than 6 months before the procedure, as this is associated with poorer outcomes.

Anti-obesity medication (AOM) administered in primary care settings produces approximately double the weight loss compared to lifestyle interventions alone, achieving an additional ~3 kg reduction.

If you are working with a primary care provider to lose weight, adding an FDA-approved anti-obesity medication to your lifestyle plan can roughly double your weight loss results compared to lifestyle changes alone. However, be prepared for the possibility that you may need to stay on the medication long-term to maintain the loss, as weight regain is common when stopping treatment.

Adjunctive semaglutide therapy significantly enhances total body weight loss and prevents post-balloon weight regain compared to intragastric balloon (IGB) alone in patients with BMI ≥ 27 kg/m².

If you are using an intragastric balloon for weight loss, adding semaglutide (a GLP-1 medication) can significantly increase your total weight loss and help you keep the weight off after the balloon is removed. The study used a specific dosing schedule starting at 0.5mg and going up to 1mg weekly, pausing while the balloon is in place, and restarting after removal. This approach helps overcome the natural weight regain that often happens after balloon removal alone.

Pharmacologic management using GLP-1 receptor agonists (specifically liraglutide), topiramate, and phentermine/topiramate is effective for treating weight regain or weight loss plateaus following bariatric surgery.

If you are regaining weight after bariatric surgery, ask your provider about GLP-1 agonists (like liraglutide) or topiramate-based therapies. Current observational data supports their use for weight optimization in this specific population.

Combining beinaglutide (0.2 mg TID) with metformin (850 mg BID) produces significantly greater weight loss and improvements in insulin sensitivity and hyperandrogenism compared to metformin monotherapy in obese women with PCOS over a 12-week period.

For obese women with PCOS who are already taking metformin but struggling with weight loss or high androgens, adding beinaglutide (starting low and titrating up) is a clinically superior strategy to staying on metformin alone. This combination leads to significantly more weight loss, better waist circumference reduction, and improved insulin sensitivity. While it involves injections, the study found that side effects were manageable and did not cause more people to quit than those taking metformin alone. This approach is particularly relevant for those who have not achieved sufficient results with lifestyle changes and metformin monotherapy.

High-protein diets promote weight loss and fat mass reduction while maintaining fat-free mass by increasing energy expenditure through diet-induced thermogenesis and stimulating anorexigenic hormones.

Consider increasing your protein intake to help with weight loss and preserving muscle. This works by boosting your metabolism and reducing hunger hormones. It is one of several effective dietary strategies.

In patients with overweight or obesity without type 2 diabetes, 1-year treatment with semaglutide 2.4 mg or tirzepatide results in clinically meaningful weight loss of 14.1% and 16.5%, respectively, in real-world clinical practice.

If you have obesity or are overweight and do not have type 2 diabetes, treatment with semaglutide (Wegovy) or tirzepatide (Zepbound/Mounjaro) for one year in a real-world setting leads to significant weight loss, averaging 14-16% of body weight. This effectiveness holds true in routine clinical practice, not just in clinical trials, although reaching the maximum dose is not guaranteed for everyone.

Semaglutide administration (1-2 mg weekly) produces significant weight loss (median 13.3% at 6 months) in adults with obesity, with efficacy maintained even at lower maintenance doses (1 mg).

Semaglutide is a highly effective treatment for obesity, producing significant weight loss even at lower maintenance doses. It requires a weekly injection and is most effective when combined with lifestyle counseling. Patients should be aware of potential gastrointestinal side effects, which are usually mild.

Adjuvant semaglutide at lower doses (≤1 mg/week) achieves clinically significant weight loss (median 7.5% TWL) in post-bariatric surgery patients with refractory obesity, with a favorable side effect profile compared to higher doses.

If you have had bariatric surgery and are experiencing weight regain or insufficient loss, ask your doctor about adjuvant semaglutide. You may not need the highest dose (2.4 mg); many patients achieve significant weight loss (around 7.5% of total body weight) at lower doses (1 mg or less). This approach is often more affordable, has fewer side effects, and is sufficient for long-term management, especially if supply of higher doses is an issue.

Post-bariatric patients with insufficient weight loss or weight regain achieve significant additional weight loss and comorbidity improvement when treated with GLP-1 receptor agonists (semaglutide or dulaglutide).

If you have had bariatric surgery and are not losing enough weight or are gaining it back, ask your doctor about GLP-1 medications like semaglutide or dulaglutide. These drugs can help you lose more weight and improve health conditions like high blood pressure and sleep apnea. They are taken as weekly injections and are generally well-tolerated, though nausea is a common side effect.

Semaglutide (Ozempic) induces significant weight loss in obese patients primarily through appetite suppression and reduced energy intake, with efficacy directly correlated to dosage.

Semaglutide is an effective tool for weight loss, working by reducing hunger and calorie intake rather than burning more fat directly. It requires a weekly injection with a specific titration schedule to manage side effects like nausea. While effective, it is not a magic bullet; long-term safety data is still emerging, and it is contraindicated for people with certain thyroid or pancreatic histories.

Daily supplementation with 650 mg of a proprietary blend of Sphaeranthus indicus and Mangifera indica extracts (LI12542F6) for 56 days significantly increases muscle strength, endurance, and lean mass in young, recreationally active males undergoing resistance training.

If you are a young male who lifts weights regularly, taking 650 mg of this specific herbal blend (LI12542F6) daily for about 8 weeks, alongside your normal training, may help you lift heavier weights and last longer on cardio compared to taking a placebo. It also appeared to increase lean muscle mass and improve hormone profiles (higher testosterone, lower cortisol) without causing side effects in this study.

Subcutaneous semaglutide (starting 0.25 mg, titrated to 1 mg weekly) significantly reduces body weight and HbA1c in patients with type 2 diabetes, with maximal efficacy observed when combined with lifestyle modifications (diet and exercise).

If you have Type 2 Diabetes, semaglutide (Ozempic) is an effective tool for losing weight and lowering blood sugar. To get the best results, take it as prescribed (starting low and building up) and combine it with a healthy diet and regular exercise. Be aware that stomach issues like nausea are common reasons people stop taking it, so talk to your doctor about managing these side effects to stay on the medication.

Semaglutide (both injectable and oral formulations) induces significant weight loss and maintains weight loss over 12-24 months in patients with type 2 diabetes and obesity/overweight.

If you have type 2 diabetes and are overweight or obese, semaglutide (either as a weekly injection or daily pill) can help you lose a significant amount of weight and keep it off for at least a year. It works best when combined with a moderate calorie-reduced diet and regular walking. Both forms are effective, so you can choose based on your preference for injections vs. pills.

Once-weekly subcutaneous TG103 injection (15.0–30.0 mg) produces statistically significant weight loss in overweight or obese adults without diabetes, with a safety profile characterized by mild, dose-dependent gastrointestinal adverse events.

TG103 is a once-weekly injection that helps overweight or obese adults lose about 5-7% of their body weight over 12 weeks without needing diet changes. The main side effects are mild stomach issues like nausea or diarrhea, which usually get better over time. It appears safe for people without diabetes, but you should discuss the risks and benefits with a doctor.

CT-388, a once-weekly signaling-biased dual GLP-1/GIP receptor agonist, produces clinically meaningful weight loss (4.7% to 8.0% over 4 weeks) and improved glycemic control in participants with overweight or obesity, with a safety profile consistent with other incretin-based therapies.

CT-388 is a once-weekly injection that helps people with overweight or obesity lose weight (4.7% to 8.0% in 4 weeks) and improves blood sugar control. It is generally well-tolerated, with most side effects being mild or moderate. This makes it a promising option for treating obesity and type 2 diabetes, though long-term data is still needed.

GZR18, a GLP-1 receptor agonist administered once-weekly or bi-weekly, induces robust body weight reductions (up to 17.8%) and improves metabolic parameters in Chinese adults with overweight or obesity.

GZR18 is a once-weekly or bi-weekly GLP-1 injection that helps overweight or obese Chinese adults lose significant weight (up to 17.8%) and improve metabolic health. It is designed to minimize side effects like nausea, making it a potentially tolerable option for those who struggle with frequent injections or severe gastrointestinal issues from other GLP-1 drugs. Consult a doctor to see if it's appropriate for you.

Phentermine monotherapy produces significantly higher rates of ≥5% weight loss compared to other anti-obesity medications (phentermine/topiramate, liraglutide, naltrexone/bupropion, lorcaserin, orlistat) over a 6-month period.

If you are struggling with obesity and lifestyle changes alone haven't worked, phentermine (up to 37.5mg daily) combined with a structured diet and exercise program is likely to produce better weight loss results than other common prescription weight loss drugs over a 6-month period. Ensure you are monitored by a doctor to manage any side effects.

Adhering to a self-prescribed low-carbohydrate diet (LCD) with <100g carbohydrates per day leads to significant improvements in Type 2 Diabetes management, including reduced HbA1c, weight loss, and medication reduction, driven by reduced hunger and improved metabolic control.

If you have Type 2 Diabetes and feel your current treatment plan (medication + standard high-carb advice) isn't working or you want to reduce medication, consider a self-prescribed low-carbohydrate diet of under 100g carbs per day. Monitor your HbA1c and weight. Use online communities for support if your healthcare provider is unsupportive. Be prepared to educate family members who may not understand your dietary choices.

Phenotype-guided pharmacotherapy (matching 'hungry gut' to GLP-1, 'hungry brain' to phentermine-topiramate, and 'slow burn' to phentermine + resistance training) yields 1.75-fold greater weight loss compared to non-phenotype-guided treatment.

If you are struggling with standard obesity treatments, ask your doctor about phenotyping. Matching your specific type of hunger (gut vs. brain vs. metabolic rate) to the right medication can significantly improve your chances of losing weight compared to a standard approach.

FDA-approved anti-obesity medications (AOMs) including GLP-1 agonists (semaglutide, liraglutide), dual agonists (tirzepatide), and others (orlistat, phentermine-topiramate) produce significant weight loss (5-15%) when combined with lifestyle interventions, representing a shift from behavioral-only approaches to targeting physiological root causes.

If you have a BMI of 30 or higher (or 27 with health issues), FDA-approved medications like semaglutide or tirzepatide can help you lose 5-15% of your body weight when combined with diet and exercise. These drugs work by targeting the hormones that control hunger and fullness, addressing the biological drivers of obesity that diet and exercise alone often cannot overcome. Consult a doctor to see if you are a candidate.